Edinburgh Research Explorer

MICA: A phase II trial examining Bermekimab (anti-IL1 alpha) effects on muscle, physical function and appetite, in lung, pancreatic or ovarian cancer

Project: Research

StatusActive
Effective start/end date1/06/1930/11/21
Total award£338,804.00
Funding organisationMRC
Period1/06/1930/11/21